CARsgen Therapeutics Reports Topline Results from P-II Study of Satricabtagene Autoleucel (Satri-cel) to Treat G/GEJ Cancer in China
Shots:
- The P-II (CT041-ST-01) study is assessing safety & efficacy of satri-cel to treat CLDN18.2+, advanced 2L+ G/GEJ cancers Chinese patients
- The trial achieved 1EP, showing significantly improved PFS with satri-cel vs SoCs (paclitaxel, docetaxel, irinotecan, apatinib, or nivolumab) plus a manageable safety profile
- Satri-cel, an autologous CAR T-cell therapy targeting CLDN 18.2, focuses on GC/GEJ and pancreatic cancer (PC). It is also being assessed under multiple trials such as P-I (CT041-CG4006), P-I adjuvant (CT041-ST-05) China trial for PC, & P-Ib/II (CT041-ST-02) trial for advanced G/PC in the US
Ref: CARsgen | Image: CARsgen
Related News:- CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
